ArticleWorld journal of gastroenterology2015
Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.
Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02596620 (The Efficacy of 10-day Metronidazole and Levofloxacin Containing Sequential Therapy and 10-day Levofloxacin-containing Triple Therapy In Second Line Helicobacter Pylori Eradication Therapies), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of 10-day Metronidazole and Levofloxacin Containing Sequential Therapy and 10-day Levofloxacin-containing Triple Therapy In Second Line Helicobacter Pylori Eradication Therapies
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prevalence of clarithromycin-resistantPeerJ · 2023Pooled it
- Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials.World journal of gastroenterology · 2016Pooled it
- Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.The American journal of gastroenterology · 2017Trial
- A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.Medicine · 2016Trial
- Research progress of potassium-competitive acid blockers in the treatment ofAnnals of medicine · 2025Review
- Emergence of amoxicillin resistance in refractoryTherapeutic advances in gastroenterology · 2025Article
- Molecular surveillance ofOne health (Amsterdam, Netherlands) · 2024Article
- Update on the second-line treatment ofTherapeutic advances in gastroenterology · 2023Review
- Prevalence, diversity and public health implications ofOne health (Amsterdam, Netherlands) · 2022Article
- Evodiamine InhibitsInternational journal of molecular sciences · 2021Article
- Trend of changes in antibiotic resistance inTherapeutic advances in gastroenterology · 2020Article
- Phenotypic and Genotypic Antibiotic Resistance Patterns inFrontiers in cellular and infection microbiology · 2020Article
- Inhibitory Effects of Menadione onInternational journal of molecular sciences · 2019Article
- First-lineInfection and drug resistance · 2019Article
- Second-line rescue treatment ofWorld journal of gastroenterology · 2018Review
- Efficacy of a 14-day quadruple-therapy regimen for third-lineInfection and drug resistance · 2018Article
- Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori.World journal of gastroenterology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine changes in the antibiotic resistance of Helicobacter pylori (H. pylori) in southern Taiwan after failure of first-line standard triple therapy.
methodsWe analyzed 137 H. pylori-infected isolates from patients who experienced eradication failure after standard first-line triple therapy from January 2010 to December 2014. The H. pylori strains were tested for susceptibility to amoxicillin, clarithromycin, levofloxacin, metronidazole and tetracycline using the E-test method. The minimal inhibitory concentration (MIC) was determined by the agar dilution test. MIC values of ≥ 0.5, ≥ 1, ≥ 1, ≥ 4 and ≥ 8 mg/L were considered to be the resistance breakpoints for amoxicillin, clarithromycin, levofloxacin, tetracycline and metronidazole, respectively.
resultsA high resistance rate was found for clarithromycin (65%-75%) and metronidazole (30%-40%) among patients who failed first-line standard therapy. The resistance levels to amoxicillin and tetracycline remained very low; however, levofloxacin resistance was as high as 37.5% in 2010 but did not increase any further during the past 5 years. The rates of resistance to these antibiotics did not show a statistically significant upward or downward trend.
conclusionAntibiotic resistance of H. pylori remains a problem for the effective eradication of this pathogen and its associated diseases in Taiwan. High clarithromycin resistance indicated that this antibiotic should not be prescribed as a second-line H. pylori eradication therapy. Moreover, levofloxacin-based second-line therapy should be used cautiously, and the local resistance rates should be carefully monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.